HIV/AIDS
Conditions
Brief summary
This study plans to learn about whether starting HIV treatment very soon after diagnosis is more beneficial than waiting until entering routine clinical care after diagnosis.
Detailed description
Randomized two arm, multi-site (three sites), open label pilot study conducted with laboratory evaluation and visits at entry, 4 weeks, 12 weeks, 24 weeks, 48 weeks and 96 weeks with laboratory evaluations and assessment if participants remain engaged in care. Participants will be randomly assigned with equal probability to one of two arms: Arm A: Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work referral. Arm B: Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
Interventions
A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.
DRUGStandard initiation of antiretroviral therapy (ART)
Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
Sponsors
Gilead Sciences
University of Colorado, Denver
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women 15 years and older in Colorado and 19 years and older in Nebraska. A waiver of parental consent is planned for individuals 15-17 in accordance with Colorado law which allows minors to consent for treatment for sexually transmitted infections, including HIV. * Reactive HIV-1 on an approved fourth generation HIV-1 antibody/antigen test within 72 hours * Any primary language with access to an interpreter by phone is included.
Exclusion criteria
* Pregnancy or intention to become pregnant in the next two years after enrollment * Symptomatic acute HIV (with fever, rash, influenza-like symptoms) * Creatinine clearance \<30 mL/min by Cockcroft-Gault equation. (Therapy initiated will be terminated promptly in individuals who are found to have creatinine clearance \<30 mL/min) * Prior history of known HIV diagnosis * Negative confirmatory HIV differentiation assays (therapy initiated will be terminated in individuals with negative tests and excluded from the primary analysis) * Allergy to bictegravir, emtricitabine or tenofovir alafenamide * Signs or symptoms of opportunistic infection with cryptococcal meningitis, tuberculosis or other infection that requires delay of initiation of antiretroviral therapy (up to the discretion of the site PI) * Vulnerable populations including prisoners and individuals without decision making capacity * Concommitant use of medications that are contraindicated with bictegravir, emtricitabine and tenofovir alafenamide including adefovir, carbamazepine, cladribine, dofetilide, fosphenytoin-phenytoin, oxcarbazepine, phenobarbital, primidone, rifampin, rifabutin, rifapentine, St. John's Wort, tipranavir
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Viral Suppression | 48 weeks | Proportion of participants with viral suppression to \<50 copies/mL at 48 weeks by FDA snapshot in the rapid-start ART arm compared to the standard of care arm. |
Countries
United States
Outcome results
None listed